Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
CAVU Biotherapies offers a comprehensive solution to prepare for, monitor, and tre...
CAVU Biotherapies offers a comprehensive soluti...
CannaKorp, Inc. is a technology start-up company that is simplifying and improving...
CannaKorp, Inc. is a technology start-up compan...
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming ...
Homology Medicines, Inc. is a genetic medicines...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-base...
Takeda Pharmaceutical Company Limited (TSE:4502...
At PRA Health Sciences, we work side-by-side with our clients, to move drug discov...
At PRA Health Sciences, we work side-by-side wi...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Join the National Investor Network and get the latest information with your interests in mind.